Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy

BackgroundThe efficacy of highly active antiretroviral therapy (HAART) determined by simultaneous monitoring over 100 cell-surface antigens overtime has not been attempted. We used an antibody microarray to analyze changes in the expression of 135 different cell-surface antigens overtime on PBMC from HIV+ patients on HAART. Two groups were chosen, one (n = 6) achieved sustainable response by maintaining below detectable plasma viremia and the other (n = 6) responded intermittently. Blood samples were collected over an average of 3 years and 5–8 time points were selected for microarray assay and statistical analysis.ResultsSignificant trends over time were observed for the expression of 7 cell surface antigens (CD2, CD3epsilon, CD5, CD95, CD36, CD27 and CD28) for combined patient groups. Between groups, expression levels of 10 cell surface antigens (CD11a, CD29, CD38, CD45RO, CD52, CD56, CD57, CD62E, CD64 and CD33) were found to be differential. Expression levels of CD9, CD11a, CD27, CD28 and CD52, CD44, CD49d, CD49e, CD11c strongly correlated with CD4+ and CD8+ T cell counts, respectively.ConclusionOur findings not only detected markers that may have potential prognostic/diagnostic values in evaluating HAART efficacy, but also showed how density of cell surface antigens could be efficiently exploited in an array-like manner in relation to HAART and HIV-infection. The antigens identified in this study should be further investigated by other methods such as flow cytometry for confirmation as biological analysis of these antigens may help further clarify their role during HAART and HIV infection.

[1]  O. Barreiro,et al.  Tetraspanins CD9 and CD81 Modulate HIV-1-Induced Membrane Fusion1 , 2006, The Journal of Immunology.

[2]  C. Figdor,et al.  Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, t , 1995, The Journal of clinical investigation.

[3]  Hayes,et al.  Alterations in blood leucocyte adhesion molecule profiles in HIV‐1 infection , 1999, Clinical and experimental immunology.

[4]  Nitin J. Karandikar,et al.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. , 2003, Blood.

[5]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[6]  R. Christopherson,et al.  Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. , 2001, Cancer research.

[7]  A. Fauci,et al.  Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes. , 1991, Journal of immunology.

[8]  T. Gallart,et al.  Protein kinase C-dependent up-regulation of CD5 surface expression on normal and lymphoblastoid T cells. , 1990, Immunology.

[9]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[10]  J. Hansen,et al.  Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. , 1998, The Journal of infectious diseases.

[11]  F. Miedema,et al.  Evidence for intact costimulation via CD28 and CD27 molecules in hyporesponsive T cells from human immunodeficiency virus‐infected individuals , 1995, European journal of immunology.

[12]  A. Riva,et al.  Increased CD36 Expression on Circulating Monocytes During HIV Infection , 2005, Journal of acquired immune deficiency syndromes.

[13]  J. Benito,et al.  CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. , 2004, AIDS research and human retroviruses.

[14]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[15]  P. Sfikakis,et al.  Expanding Role of Circulating Adhesion Molecules in Assessing Prognosis and Treatment Response in Human Immunodeficiency Virus Infection , 2004, Clinical Diagnostic Laboratory Immunology.

[16]  Dominic E Dwyer,et al.  Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages , 2007, Retrovirology.

[17]  R. Solana,et al.  NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56 , 2002, AIDS.

[18]  PD-1 Expression on HIV-Specific T Cells Is Associated With T-Cell Exhaustion and Disease Progression , 2007, Pediatrics.

[19]  David P. Kreil,et al.  Conservation of unique cell-surface CD antigen mosaics in HIV-1-infected individuals. , 2005, Blood.

[20]  J. Routy,et al.  4-1BBL Induces TNF Receptor-Associated Factor 1-Dependent Bim Modulation in Human T Cells and Is a Critical Component in the Costimulation-Dependent Rescue of Functionally Impaired HIV-Specific CD8 T Cells1 , 2007, The Journal of Immunology.

[21]  S. Crowe,et al.  Expression of CD11/CD18 and ICAM‐1 on monocytes and lymphocytes of HIV‐1‐infected individuals , 1994, Journal of leukocyte biology.

[22]  K. Wasserman,et al.  Expression of surface markers on alveolar macrophages from symptomatic patients with HIV infection as detected by flow cytometry. , 1994, Chest.

[23]  A. Landay,et al.  Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. , 1995, Cytometry.

[24]  H. Arnesen,et al.  Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. , 2004, Clinical biochemistry.

[25]  M. Sinet,et al.  Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy , 1998, AIDS.

[26]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[27]  C. Rapp,et al.  Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro , 2002, AIDS.

[28]  R. Detels,et al.  Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change. , 1991, Clinical immunology and immunopathology.

[29]  C. Tsoukas,et al.  Markers predicting progression of human immunodeficiency virus-related disease , 1994, Clinical Microbiology Reviews.

[30]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[31]  E. Rosenberg,et al.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.

[32]  H. D. Patterson,et al.  Recovery of inter-block information when block sizes are unequal , 1971 .

[33]  A. Rice,et al.  Identification of LKLF-regulated genes in quiescent CD4+ T lymphocytes. , 2005, Molecular immunology.

[34]  N. Mackman,et al.  Integrin regulation of an inflammatory effector gene. Direct induction of the tissue factor promoter by engagement of beta 1 or alpha 4 integrin chains. , 1995, Journal of immunology.

[35]  F. Chiodi,et al.  Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV‐1‐infected subjects , 2002, Clinical and experimental immunology.

[36]  N. Liabakk,et al.  Serum Levels of Tumor Necrosis Factor-α (TNFα) and Soluble TNF Receptors in Human Immunodeficiency Virus Type 1 Infection-Correlations to Clinical, Immunologic, and Virologic Parameters , 1994 .

[37]  M. Jayson,et al.  Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. , 1995, British journal of rheumatology.

[38]  J. Ritz,et al.  Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Xiang-An Li,et al.  HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. , 2003, The Journal of clinical investigation.

[40]  N. Liabakk,et al.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. , 1994, The Journal of infectious diseases.

[41]  S. Crowe,et al.  The Mechanism Underlying Defective Fcγ Receptor-Mediated Phagocytosis by HIV-1-Infected Human Monocyte-Derived Macrophages1 , 2007, The Journal of Immunology.

[42]  R. Detels,et al.  Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. , 1989, Journal of acquired immune deficiency syndromes.

[43]  R. Christopherson,et al.  Identification of repertoires of surface antigens on leukemias using an antibody microarray , 2003, Proteomics.

[44]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.